Please assess the completion status of the following clinical trial:

Trial Title: The Effects of Milnacipran on Sleep Disturbance in Fibromyalgia

Study Design Characteristics:
- Allocation: RANDOMIZED
- Intervention Model: CROSSOVER
- Observational Model: None
- Primary Purpose: TREATMENT
- Time Perspective: None
- Masking: DOUBLE
- Phase: PHASE4
- Number of Arms: 2.0

Eligibility Criteria:
Inclusion Criteria:~1. Men or women at least 18 years or older~2. Diagnosis of fibromyalgia~3. Clinically significant sleep disturbance, defined as difficulty in maintaining sleep (wake after sleep onset and arousal index) at least three times per week for at least one month~4. Understand and willing to cooperate with the study procedures~5. Maintain a normal sleep schedule, with daytime-awake and nighttime-sleep schedule, with customary bedtime between 9 PM and midnight, and rise time 5 AM and 9 AM~6. Patients who are able to speak, read, and understand English language and able to follow the study protocol, and are able to sign the informed consent~Exclusion Criteria:~1. Subject has any of the following medical conditions:~   Liver disease, blood disorder, autoimmune disease, endocrine, cardiovascular, hypertension, renal, hepatic, gastrointestinal, or neurological disorder, active peptic ulcer or inflammatory bowel disease~2. Significant sleep apnea~3. Periodic leg movement disorder (PLMD) or restless legs syndrome (RLS)~4. Any form of severe psychiatric illness, moderate to severe depression, including significant risk of suicide~5. Patients with uncontrolled glaucoma~6. Inability to discontinue the prohibited medications~7. Female of childbearing potential not using birth control measures; or lactating.~8. History of alcohol, narcotic, benzodiazepines or other substance abuse within the past one year.~9. Patient on prohibited medication will include but not limited to:~   * Anxiolytics, anti-convulsants, antipsychotics, lithium, barbiturates, anti-histamines, monoamine oxidase inhibitors, or medications that affect sleep~  * Any prescription or over the counter stimulants~  * Medications that are contraindicated with the use of milnacipran~10. Excessive caffeine use, defined as a consumption of more than 500 mg of caffeine or other xanthines, smoking \>1/2 a pack/day or alcohol use \>14 units/week~11. History of allergy to milnacipran.

- Gender: ALL
- Minimum Age: 18 Years
- Maximum Age: None
- Healthy Volunteers: f

Study Arms:
- milnacipran (Type: EXPERIMENTAL): Drug: milnacipran 7-day dose escalation, 28- day treatment with milnacipran 50 mg and 7-day taper period before or after crossover to placebo
- placebo (Type: PLACEBO_COMPARATOR): Drug: placebo 45-day placebo treatment before or after crossover to milnacipran

Based on this trial design, predict the completion outcome and termination type (if applicable).